{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T13:04:31Z","timestamp":1781787871874,"version":"3.54.5"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T00:00:00Z","timestamp":1734566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T00:00:00Z","timestamp":1734566400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Appl Health Econ Health Policy"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s40258-024-00937-6","type":"journal-article","created":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T18:59:14Z","timestamp":1734634754000},"page":"183-195","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Cost-Effective and Sustainable Drug Use in Hospitals: A Systematic and Practice-Based Approach"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-1497-3033","authenticated-orcid":false,"given":"Michiel","family":"Zietse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon L.","family":"van der Zeeuw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Sophie Klein","family":"Gebbink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemarie C.","family":"de Vries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Rose B. S.","family":"Crombag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roelof W. F.","family":"van Leeuwen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maaike J.","family":"Hoedemakers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,19]]},"reference":[{"key":"937_CR1","unstructured":"IQVIA Institute for Human Data Science. Drug expenditure dynamics 1995\u20132020: understanding medicine spending in context. 2021. https:\/\/www.iqvia.com\/insights\/the-iqviainstitute\/reports\/drug-expenditure-dynamics. Accessed Nov 2024."},{"key":"937_CR2","unstructured":"SiRM. Een Steeds Groter Stuk Van De taart: prognose uitgaven add-on geneesmiddelen 2022-2026. Utrecht: SiRM; 2022. https:\/\/www.sirm.nl\/docs\/Uitgavenprognose-add-on-geneesmiddelen-hoofdrapport-juli-2022.pdf. Accessed Nov 2024."},{"key":"937_CR3","unstructured":"IQVIA Institute for Human Data Science. The global use of medicines 2024: outlook to 2028. 2024. https:\/\/www.iqvia.com\/insights\/the-iqvia-institute\/reports-and-publications\/reports\/the-global-use-of-medicines-2024-outlook-to-2028. Accessed Nov 2024."},{"issue":"1","key":"937_CR4","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1186\/s12913-020-05086-9","volume":"20","author":"JJG Wammes","year":"2020","unstructured":"Wammes JJG, Frederix G, Govaert P, Determann D, Evers S, Paulus A, et al. Case-studies of displacement effects in Dutch hospital care. BMC Health Serv Res. 2020;20(1):263.","journal-title":"BMC Health Serv Res"},{"key":"937_CR5","doi-asserted-by":"publisher","first-page":"1264951","DOI":"10.3389\/fphar.2023.1264951","volume":"14","author":"A Dane","year":"2023","unstructured":"Dane A, van Leeuwen R, Hoedemakers M, van der Kuy H, Sleijfer S. Combatting the rising costs of cancer drugs; interventions from a university hospital\u2019s perspective. Front Pharmacol. 2023;14:1264951.","journal-title":"Front Pharmacol"},{"issue":"8","key":"937_CR6","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1001\/jamaoncol.2019.1341","volume":"5","author":"MJ Ratain","year":"2019","unstructured":"Ratain MJ, Goldstein DA, Lichter AS. Interventional pharmacoeconomics: a new discipline for a cost-constrained environment. JAMA Oncol. 2019;5(8):1097\u20138.","journal-title":"JAMA Oncol"},{"issue":"3","key":"937_CR7","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1002\/cpt.1853","volume":"108","author":"AV Serritella","year":"2020","unstructured":"Serritella AV, Strohbehn GW, Goldstein DA, Lichter AS, Ratain MJ. Interventional pharmacoeconomics: a novel mechanism for unlocking value. Clin Pharmacol Ther. 2020;108(3):487\u201393.","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"937_CR8","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1200\/OP.23.00227","volume":"19","author":"SI Jacobson","year":"2023","unstructured":"Jacobson SI, Kacew AJ, Knoebel RW, Hsieh PH, Ratain MJ, Strohbehn GW. Alternative trastuzumab dosing schedules are associated with reductions in health care greenhouse gas emissions. JCO Oncol Pract. 2023;19(9):799\u2013807.","journal-title":"JCO Oncol Pract."},{"key":"937_CR9","unstructured":"European Medicines Agency, Good practice guidance for patient and healthcare professional organisations on the prevention of shortages of medicines for human use. https:\/\/www.ema.europa.eu\/en\/documents\/other\/good-practice-guidance-patient-and-healthcare-professional-organisations-prevention-shortages-medicines-human-use_en.pdf. Accessed Nov 2024."},{"issue":"1","key":"937_CR10","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/hpm.3542","volume":"38","author":"MS Koushki","year":"2023","unstructured":"Koushki MS, Goudarzi R, Amiresmaili M, Nekooei Moghaddam M, Yazdi-Feyzabadi V, Talebian A. Strategies of drugs cost containment in hospital: a systematic literature review. Int J Health Plann Manage. 2023;38(1):7\u201321.","journal-title":"Int J Health Plann Manage"},{"issue":"1","key":"937_CR11","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s43441-022-00436-7","volume":"57","author":"N Beer","year":"2023","unstructured":"Beer N, Kaae S, Genina N, Sporrong SK, Alves TL, Hoebert J, et al. Magistral compounding with 3D printing: a promising way to achieve personalized medicine. Ther Innov Regul Sci. 2023;57(1):26\u201336.","journal-title":"Ther Innov Regul Sci."},{"key":"937_CR12","doi-asserted-by":"crossref","unstructured":"Eisenmann ED, Talebi Z, Sparreboom A, Baker SD. Boosting the oral bioavailability of anticancer drugs through intentional drug-drug interactions. Basic Clin Pharmacol Toxicol. 2022;130(Suppl. 1):23\u201335.","DOI":"10.1111\/bcpt.13623"},{"issue":"2","key":"937_CR13","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s10198-011-0302-6","volume":"13","author":"M Westerdijk","year":"2012","unstructured":"Westerdijk M, Zuurbier J, Ludwig M, Prins S. Defining care products to finance health care in the Netherlands. Eur J Health Econ. 2012;13(2):203\u201321.","journal-title":"Eur J Health Econ"},{"key":"937_CR14","unstructured":"Dutch National Healthcare Institute. Genees: en hulpmiddelen Informatie Project (GIP) database.: https:\/\/www.gipdatabank.nl\/. Accessed Nov 2024."},{"issue":"4","key":"937_CR15","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/S2468-1253(22)00434-4","volume":"8","author":"RCA van Linschoten","year":"2023","unstructured":"van Linschoten RCA, Jansen FM, Pauwels RWM, Smits LJT, Atsma F, Kievit W, et al. Increased versus conventional adalimumab dose interval for patients with Crohn\u2019s disease in stable remission (LADI): a pragmatic, open-label, non-inferiority, randomised controlled trial. Lancet Gastroenterol Hepatol. 2023;8(4):343\u201355.","journal-title":"Lancet Gastroenterol Hepatol."},{"issue":"6","key":"937_CR16","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s40273-015-0380-x","volume":"34","author":"J Mestre-Ferrandiz","year":"2016","unstructured":"Mestre-Ferrandiz J, Towse A, Berdud M. Biosimilars: how can payers get long-term savings? Pharmacoeconomics. 2016;34(6):609\u201316.","journal-title":"Pharmacoeconomics"},{"key":"937_CR17","unstructured":"HOVON 161. https:\/\/hovon.nl\/nl\/trials\/ho161-1. Accessed Nov 2024."},{"issue":"11","key":"937_CR18","doi-asserted-by":"publisher","first-page":"3700","DOI":"10.1093\/rheumatology\/kead128","volume":"62","author":"S Sener","year":"2023","unstructured":"Sener S, Cam V, Batu ED, Kasap Cuceoglu M, Balik Z, Aliyev E, et al. Feasibility of canakinumab withdrawal in colchicine-resistant familial Mediterranean fever. Rheumatology (Oxford). 2023;62(11):3700\u20135.","journal-title":"Rheumatology (Oxford)"},{"key":"937_CR19","unstructured":"Center for Drug Evaluation and Research. Clinical pharmacology and biopharmaceutics review(s): application number 761036Orig1s000. 2015. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2015\/761036Orig1s000ClinPharmR.pdf. Accessed Nov 2024."},{"issue":"3","key":"937_CR20","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1093\/bjd\/ljad159","volume":"189","author":"LS Spekhorst","year":"2023","unstructured":"Spekhorst LS, Boesjes CM, Loman L, Zuithoff NPA, Bakker DS, Kamphuis E, et al. Successful tapering of dupilumab in patients with atopic dermatitis with low disease activity: a large pragmatic daily practice study from the BioDay registry. Br J Dermatol. 2023;189(3):327\u201335.","journal-title":"Br J Dermatol"},{"issue":"6","key":"937_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-072363","volume":"13","author":"A Donners","year":"2023","unstructured":"Donners A, van der Zwet K, Egberts ACG, Fijnvandraat K, Mathot R, Kruis I, et al. DosEmi study protocol: a phase IV, multicentre, open-label, crossover study to evaluate non-inferiority of pharmacokinetic-guided reduced dosing compared with conventional dosing of emicizumab in people with haemophilia A. BMJ Open. 2023;13(6): e072363.","journal-title":"BMJ Open"},{"issue":"8","key":"937_CR22","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1016\/j.cgh.2021.03.037","volume":"20","author":"RWM Pauwels","year":"2022","unstructured":"Pauwels RWM, van der Woude CJ, Nieboer D, Steyerberg EW, Casanova MJ, Gisbert JP, et al. Prediction of relapse after anti-tumor necrosis factor cessation in Crohn\u2019s disease: individual participant data meta-analysis of 1317 patients from 14 studies. Clin Gastroenterol Hepatol. 2022;20(8):1671-86.e16.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"937_CR23","unstructured":"Netherlands Government, Medicines Act (Geneesmiddelenwet), Article 3. https:\/\/wetten.overheid.nl\/jci1.3:c:BWBR0021672&paragraaf=2&artikel=3&z=2018-08-01&g=2018-08-01. Accessed Nov 2024."},{"key":"937_CR24","unstructured":"European Medicines Agency. Guideline on bioequivalence. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-investigation-bioequivalence-rev1_en.pdf. Accessed Nov 2024."},{"key":"937_CR25","doi-asserted-by":"crossref","unstructured":"Figgins BS, Aitken SL, Whited LK. Optimization of intravenous immune globulin use at a comprehensive cancer center. Am J Health Syst Pharm. 2019;76:S102\u20136.","DOI":"10.1093\/ajhp\/zxz233"},{"issue":"8","key":"937_CR26","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1177\/13524585241258692","volume":"30","author":"I Smets","year":"2024","unstructured":"Smets I, Versteegh M, Huygens S, Wokke B, Smolders J. Benefits of early highly effective versus escalation treatment strategies in relapsing multiple sclerosis estimated using a treatment-sequence model. Mult Scler. 2024;30(8):1016\u201325.","journal-title":"Mult Scler"},{"issue":"12","key":"937_CR27","doi-asserted-by":"publisher","first-page":"e552","DOI":"10.1016\/S1470-2045(22)00554-X","volume":"23","author":"R Malmberg","year":"2022","unstructured":"Malmberg R, Zietse M, Dumoulin DW, Hendrikx J, Aerts J, van der Veldt AAM, et al. Alternative dosing strategies for immune checkpoint inhibitors to improve cost-effectiveness: a special focus on nivolumab and pembrolizumab. Lancet Oncol. 2022;23(12):e552\u201361.","journal-title":"Lancet Oncol"},{"issue":"3","key":"937_CR28","first-page":"205521732311893","volume":"9","author":"I Smets","year":"2023","unstructured":"Smets I, Versteegh M, Huygens S, Corsten C, Wokke B, Smolders J. Health-economic benefits of anti-CD20 treatments in relapsing multiple sclerosis estimated using a treatment-sequence model. Mult Scler J Exp Transl Clin. 2023;9(3):20552173231189400.","journal-title":"Mult Scler J Exp Transl Clin."},{"key":"937_CR29","doi-asserted-by":"crossref","unstructured":"Alizadeh Aghdam M, Pieterse RH, Kentie PA, Rijken F, Knulst AC, Rockmann H. Effective omalizumab interval prolongation in the treatment of chronic urticaria. J Allergy Clin Immunol Pract. 2020;8(10):3667\u20138 e1.","DOI":"10.1016\/j.jaip.2020.06.056"},{"key":"937_CR30","unstructured":"Center for Drug Evaluation and Research. Clinical pharmacology and biopharmaceutics review(s): application number 208065Orig1s000. 2015. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2015\/208065Orig1s000ClinPharmR.pdf. Accessed Nov 2024."},{"key":"937_CR31","unstructured":"Center for Drug Evaluation and Research. Clinical pharmacology and biopharmaceutics review(s): application number 761044Orig1s000. 2016. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2016\/761044Orig1s000ClinPharmR.pdf. Accessed Nov 2024."},{"issue":"8","key":"937_CR32","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1111\/apt.13547","volume":"43","author":"NA Kennedy","year":"2016","unstructured":"Kennedy NA, Warner B, Johnston EL, Flanders L, Hendy P, Ding NS, et al. Relapse after withdrawal from anti-TNF therapy for inflammatory bowel disease: an observational study, plus systematic review and meta-analysis. Aliment Pharmacol Ther. 2016;43(8):910\u201323.","journal-title":"Aliment Pharmacol Ther"},{"key":"937_CR33","unstructured":"European Medicines Agency. Summary of product characteristics, Kiovig. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/kiovig-epar-product-information_en.pdf. Accessed Mar 2024."},{"issue":"6","key":"937_CR34","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1592\/phco.26.6.813","volume":"26","author":"T Koleba","year":"2006","unstructured":"Koleba T, Ensom MH. Pharmacokinetics of intravenous immunoglobulin: a systematic review. Pharmacotherapy. 2006;26(6):813\u201327.","journal-title":"Pharmacotherapy"},{"key":"937_CR35","doi-asserted-by":"crossref","unstructured":"Rocchio MA, Hussey AP, Southard RA, Szumita PM. Impact of ideal body weight dosing for all inpatient i.v. immune globulin indications. Am J Health Syst Pharm. 2013;70(9):751\u20132.","DOI":"10.2146\/ajhp110744"},{"issue":"2","key":"937_CR36","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1177\/1060028016673071","volume":"51","author":"MA Rocchio","year":"2017","unstructured":"Rocchio MA, Schurr JW, Hussey AP, Szumita PM. Intravenous immune globulin stewardship program at a tertiary academic medical center. Ann Pharmacother. 2017;51(2):135\u20139.","journal-title":"Ann Pharmacother"},{"issue":"4","key":"937_CR37","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S1474-4422(20)30494-4","volume":"20","author":"C Walgaard","year":"2021","unstructured":"Walgaard C, Jacobs BC, Lingsma HF, Steyerberg EW, van den Berg B, Doets AY, et al. Second intravenous immunoglobulin dose in patients with Guillain-Barre syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2021;20(4):275\u201383.","journal-title":"Lancet Neurol"},{"issue":"12","key":"937_CR38","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1002\/phar.2047","volume":"37","author":"SE Stump","year":"2017","unstructured":"Stump SE, Schepers AJ, Jones AR, Alexander MD, Auten JJ. Comparison of weight-based dosing strategies for intravenous immunoglobulin in patients with hematologic malignancies. Pharmacotherapy. 2017;37(12):1530\u20136.","journal-title":"Pharmacotherapy"},{"issue":"3","key":"937_CR39","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1177\/1060028019880300","volume":"54","author":"JW Grindeland","year":"2020","unstructured":"Grindeland JW, Grindeland CJ, Moen C, Leedahl ND, Leedahl DD. Outcomes associated with standardized ideal body weight dosing of intravenous immune globulin in hospitalized patients: a multicenter study. Ann Pharmacother. 2020;54(3):205\u201312.","journal-title":"Ann Pharmacother"},{"issue":"6","key":"937_CR40","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1007\/s10875-012-9720-1","volume":"32","author":"H Abolhassani","year":"2012","unstructured":"Abolhassani H, Sadaghiani MS, Aghamohammadi A, Ochs HD, Rezaei N. Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta analysis. J Clin Immunol. 2012;32(6):1180\u201392.","journal-title":"J Clin Immunol"},{"issue":"1","key":"937_CR41","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s10875-006-8905-x","volume":"26","author":"U Nicolay","year":"2006","unstructured":"Nicolay U, Kiessling P, Berger M, Gupta S, Yel L, Roifman CM, et al. Health-related quality of life and treatment satisfaction in North American patients with primary immunedeficiency diseases receiving subcutaneous IgG self-infusions at home. J Clin Immunol. 2006;26(1):65\u201372.","journal-title":"J Clin Immunol"},{"issue":"1","key":"937_CR42","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s13223-022-00735-6","volume":"18","author":"B Ritchie","year":"2022","unstructured":"Ritchie B, Martins KJB, Tran DT, Blain H, Richer L, Klarenbach SW. Economic impact of self-administered subcutaneous versus clinic-administered intravenous immunoglobulin G therapy in Alberta, Canada: a population-based cohort study. Allergy Asthma Clin Immunol. 2022;18(1):99.","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"11","key":"937_CR43","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.39868","volume":"5","author":"MP Socal","year":"2022","unstructured":"Socal MP, Cordeiro T, Anderson GF, Bai G. Estimating savings opportunities from therapeutic substitutions of high-cost generic medications. JAMA Netw Open. 2022;5(11): e2239868.","journal-title":"JAMA Netw Open"},{"key":"937_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.758210","volume":"12","author":"Y Polak","year":"2021","unstructured":"Polak Y, Jacobs BAW, Kemper EM. Pharmacy compounded medicines for patients with rare diseases: lessons learned from chenodeoxycholic acid and cholic acid. Front Pharmacol. 2021;12: 758210.","journal-title":"Front Pharmacol"},{"issue":"33","key":"937_CR45","doi-asserted-by":"publisher","first-page":"3863","DOI":"10.1200\/JCO.20.00131","volume":"38","author":"DM Waterhouse","year":"2020","unstructured":"Waterhouse DM, Garon EB, Chandler J, McCleod M, Hussein M, Jotte R, et al. Continuous versus 1-year fixed-duration nivolumab in previously treated advanced non-small-cell lung cancer: CheckMate 153. J Clin Oncol. 2020;38(33):3863\u201373.","journal-title":"J Clin Oncol"},{"key":"937_CR46","first-page":"10400","volume":"20","author":"EM Smale","year":"2021","unstructured":"Smale EM, Egberts TCG, Heerdink ER, van den Bemt BJF, Bekker CL. Waste-minimising measures to achieve sustainable supply and use of medication. Sustain Chem Pharm. 2021;20:10400.","journal-title":"Sustain Chem Pharm."},{"issue":"7","key":"937_CR47","doi-asserted-by":"publisher","first-page":"E646","DOI":"10.1200\/JOP.2017.022905","volume":"13","author":"CYW Leung","year":"2017","unstructured":"Leung CYW, Cheung MC, Charbonneau LF, Prica A, Ng P, Chan KKW. Financial impact of cancer drug wastage and potential cost savings from mitigation strategies. J Oncol Pract. 2017;13(7):E646\u201352.","journal-title":"J Oncol Pract"},{"key":"937_CR48","doi-asserted-by":"crossref","unstructured":"Sonke GS, van Ommen-Nijhof A, Wortelboer N, et al. Early versus deferred use of CDK4\/6 inhibitors in advanced breast cancer. Nature  2024;636:474\u201380.","DOI":"10.1038\/s41586-024-08035-2"},{"key":"937_CR49","doi-asserted-by":"crossref","unstructured":"Pacey S, Warner J, Li Wan Po A. A multidisciplinary approach to hospital-based drug cost containment. J Clin Pharm Ther. 1998;23(3):203\u201311.","DOI":"10.1046\/j.1365-2710.1998.00153.x"},{"issue":"5","key":"937_CR50","doi-asserted-by":"publisher","first-page":"377","DOI":"10.2165\/00019053-199201050-00009","volume":"1","author":"PI Pillans","year":"1992","unstructured":"Pillans PI, Conry I, Gie BE. Drug cost containment at a large teaching hospital. Pharmacoeconomics. 1992;1(5):377\u201382.","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"937_CR51","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1001\/jamaoncol.2023.4865","volume":"10","author":"EM Smale","year":"2024","unstructured":"Smale EM, van den Bemt BJF, Heerdink ER, Desar IME, Egberts TCG, Bekker CL, et al. Cost savings and waste reduction through redispensing unused oral anticancer drugs: the ROAD Study. JAMA Oncol. 2024;10(1):87\u201394.","journal-title":"JAMA Oncol"},{"issue":"1","key":"937_CR52","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s41669-022-00361-3","volume":"7","author":"C McCloskey","year":"2023","unstructured":"McCloskey C, Ortega MT, Nair S, Garcia MJ, Manevy F. A systematic review of time and resource use costs of subcutaneous versus intravenous administration of oncology biologics in a hospital setting. Pharmacoecon Open. 2023;7(1):3\u201336.","journal-title":"Pharmacoecon Open."},{"issue":"5","key":"937_CR53","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s40259-018-0295-0","volume":"32","author":"B Bittner","year":"2018","unstructured":"Bittner B, Richter W, Schmidt J. Subcutaneous administration of biotherapeutics: an overview of current challenges and opportunities. BioDrugs. 2018;32(5):425\u201340.","journal-title":"BioDrugs"},{"issue":"4","key":"937_CR54","doi-asserted-by":"publisher","first-page":"947","DOI":"10.21037\/tlcr-24-63","volume":"13","author":"Y Inoue","year":"2024","unstructured":"Inoue Y. Subcutaneous delivery of immune checkpoint inhibitors: new route replacing intravenous administration? Transl Lung Cancer Res. 2024;13(4):947\u201351.","journal-title":"Transl Lung Cancer Res."},{"issue":"7","key":"937_CR55","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1007\/s10198-023-01648-w","volume":"25","author":"G Kirshner","year":"2024","unstructured":"Kirshner G, Makai P, Brouns C, Timmers L, Kemp R. The impact of an \u2018evergreening\u2019 strategy nearing patent expiration on the uptake of biosimilars and public healthcare costs: a case study on the introduction of a second administration form of trastuzumab in the Netherlands. Eur J Health Econ. 2024;25(7):1147\u201363.","journal-title":"Eur J Health Econ"},{"issue":"4","key":"937_CR56","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1097\/PPO.0000000000000461","volume":"26","author":"DA Goldstein","year":"2020","unstructured":"Goldstein DA, Strohbehn GW, Serritella AV, Hyman DA, Lichter AS, Ratain MJ. Interventional pharmacoeconomics. Cancer J. 2020;26(4):330\u20134.","journal-title":"Cancer J"},{"issue":"1","key":"937_CR57","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1007\/s11096-017-0424-8","volume":"39","author":"CL Bekker","year":"2017","unstructured":"Bekker CL, Gardarsdottir H, Egberts TCG, Bouvy ML, van den Bemt BJF. Redispensing of medicines unused by patients: a qualitative study among stakeholders. Int J Clin Pharm Net. 2017;39(1):196\u2013204.","journal-title":"Int J Clin Pharm Net."},{"issue":"2","key":"937_CR58","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0293264","volume":"19","author":"R Heine","year":"2024","unstructured":"Heine R, Thielen FW, Mathijssen RHJ, van Leeuwen RWF, Franken MG, Uyl-de Groot CA. Applying a cost-based pricing model for innovative cancer treatments subject to indication expansion: a case study for pembrolizumab and daratumumab. PLoS ONE. 2024;19(2): e0293264.","journal-title":"PLoS ONE"}],"container-title":["Applied Health Economics and Health Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-024-00937-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40258-024-00937-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-024-00937-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T15:47:36Z","timestamp":1739461656000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40258-024-00937-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,19]]},"references-count":58,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["937"],"URL":"https:\/\/doi.org\/10.1007\/s40258-024-00937-6","relation":{},"ISSN":["1175-5652","1179-1896"],"issn-type":[{"value":"1175-5652","type":"print"},{"value":"1179-1896","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,19]]},"assertion":[{"value":"28 November 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article was not supported by external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Annemarie C. de Vries has served on advisory boards for Takeda, Janssen, Bristol Myers Squibb, Abbvie, Pfizer, Lilly, and Galapagos and has received unrestricted research grants from Takeda, Janssen, Dr Falk, and Pfizer outside the submitted work. Roelof W.F. van Leeuwen reports research grants (all paid to the institution) from Bristol Myers Squibb, Pfizer, consulting fees from Bristol Myers Squibb, Roche, Pierre Fabre, AstraZeneca, Pfizer, Novartis, and Eli Lilly, speaker fees from AstraZeneca, and travel support from Ipsen, all outside the submitted work. Michiel Zietse, Shannon L. van der Zeeuw, Anne-Sophie Klein Gebbink, Marie-Rose B.S. Crombag, and Maaike J. Hoedemakers have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/competing interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The data generated during the current study are available in the text and ESM. Further data can be made available from the corresponding author on reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"MBSC, RWFL, and MJH conceptualized and designed this study. SZ, MBSC, RWFL, and MJH contributed to the data collection, MZ, SZ, MBSC, RWFL, and MJH contributed to the analysis. MZ, SZ, MBSC, RWFL, and MJH reviewed the available data. MZ, SZ, ASKG, ACV, MBSC, RWFL, and MJH drafted the manuscript. All authors read, commented, and approved the final manuscript, prior to submission.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}